| Title |
Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission
|
|---|---|
| Published in |
Tumor Biology, August 2015
|
| DOI | 10.1007/s13277-015-3872-6 |
| Pubmed ID | |
| Authors |
Zhanshan Cha, Chen Li, Yan Zang, Haihui Gu, Huijun Guo, Jinqi Li, Yuan Fang, Thomas F. Petersen, Jing Li, Richard O. Karas, Michele L. Hamilton, Baohua Qian |
| Abstract |
Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen. Treatment using rituximab in combination with chemotherapy has dramatically improved overall survival rate of diffuse large B cell lymphoma (DLBCL). Since rituximab can deplete both lymphoma B cells and normal B cells, how rituximab-treatment affects normal B cell function in DLBCL patients under remission is unclear. Here, we examined peripheral blood B cell composition and antigen-specific B cell responses in DLBCL patients in remission and observed reductions in the frequencies of total B cell as well as several major B cell subsets, including CD19(+)IgD(+) naive B cells, CD19(+)IgD(-)CD27(+) memory B cells, and CD19(lo)CD27(hi) plasmablasts. Moreover, tetanus toxin (TT)-specific B cell proliferation was reduced in DLBCL patients in remission. On the other hand, HA-specific IgG-secreting B cell responses could be stimulated by influenza vaccination in DLBCL patients in remission, demonstrating that the machinery for generating de novo adaptive B cell responses was functional in DLBCL patients in remission. Our results provided insights in normal B cell function in DLBCL patients in remission. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 10% |
| Unknown | 9 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 20% |
| Student > Ph. D. Student | 2 | 20% |
| Other | 1 | 10% |
| Student > Bachelor | 1 | 10% |
| Student > Master | 1 | 10% |
| Other | 1 | 10% |
| Unknown | 2 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 40% |
| Agricultural and Biological Sciences | 1 | 10% |
| Biochemistry, Genetics and Molecular Biology | 1 | 10% |
| Psychology | 1 | 10% |
| Immunology and Microbiology | 1 | 10% |
| Other | 0 | 0% |
| Unknown | 2 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2015.
All research outputs
#7,131,525
of 22,821,814 outputs
Outputs from Tumor Biology
#357
of 2,622 outputs
Outputs of similar age
#83,907
of 264,425 outputs
Outputs of similar age from Tumor Biology
#20
of 175 outputs
Altmetric has tracked 22,821,814 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,622 research outputs from this source. They receive a mean Attention Score of 2.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,425 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 175 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.